AdaptHealth Corp. (AHCO) vs Jade Biosciences, Inc. (JBIO)
A side-by-side comparison of AdaptHealth Corp. and Jade Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AHCO
AdaptHealth Corp.
$5.75HealthcareDelayed quote: Oct 6, 2026, 3:45 PM EDT
JBIO
Jade Biosciences, Inc.
$13.18HealthcareDelayed quote: Oct 6, 2026, 3:45 PM EDT
Total return — AHCO vs JBIO
growth of $100 · dividends reinvested · last 5yAHCO -79.8% (-27.4%/yr)JBIO -97.8% (-53.5%/yr)AHCO compounded faster over this window
Log scale — wide-divergence pair
AHCO JBIO
AHCO vs JBIO: by the numbers
- •JBIO is the larger company ($802M vs $782M market cap).
- •Both run net losses; JBIO's is the smaller (0.00% vs -7.58% net margin).
Metrics side by side
Valuation
| Metric | AHCO | JBIO |
|---|---|---|
| P/S ratio | 0.26 | N/A |
| P/B ratio | 0.57 | 1.82 |
| EV / EBITDA | 6.62 | N/A |
| FCF yield | 12.50% | N/A |
Profitability
| Metric | AHCO | JBIO |
|---|---|---|
| Gross margin | 10.37% | 0.00% |
| Operating margin | -0.31% | 0.00% |
| Net margin | -7.58% | 0.00% |
| ROE | -16.56% | -34.83% |
| ROIC | -0.26% | -37.39% |
Growth (annualized)
| Metric | AHCO | JBIO |
|---|---|---|
| Revenue CAGR (5Y) | 11.68% | N/A |
| FCF CAGR (5Y) | 7.07% | N/A |
| Total return CAGR (5Y) | -24.65% | -52.65% |
Frequently asked
- How have AHCO and JBIO total returns compared?
- Over the past 5 years, AHCO delivered -24.65% and JBIO delivered -52.65% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
AdaptHealth ROEJade Biosciences ROEAdaptHealth operating marginJade Biosciences operating marginAdaptHealth revenue growthJade Biosciences revenue growthAdaptHealth free cash flowJade Biosciences free cash flow
AdaptHealth & Jade Biosciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.